Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 56 for:    insys

A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03827642
Recruitment Status : Completed
First Posted : February 1, 2019
Last Update Posted : February 1, 2019
Sponsor:
Information provided by (Responsible Party):
INSYS Therapeutics Inc

Brief Summary:
The main objective of this study was to compare the bioavailability of two test formulations of Naloxone Nasal Spray with the reference formulations of Naloxone HCl IV and IM injection under fasted conditions.

Condition or disease Intervention/treatment Phase
Healthy Volunteer Drug: Treatment A: Naloxone Nasal Spray Drug: Treatment B: Naloxone Nasal Spray Drug: Treatment C: Naloxone HCl Intravenous (IV) Injection Drug: Treatment D: Naloxone HCl Intramuscular (IM) Injection Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Randomized, Crossover, Comparative Bioavailability Study of Naloxone Nasal Spray and Naloxone Hydrochloride Intravenous and Intramuscular Injection in Healthy Volunteers
Actual Study Start Date : April 23, 2018
Actual Primary Completion Date : May 6, 2018
Actual Study Completion Date : May 6, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort 1: Treatment Sequence A-D-C-B
Participants received Treatment A on Day 1 of Period 1, Treatment D on Day 1 of Period 2, Treatment C on Day 1 of Period 3 and Treatment B on Day 1 of Period 4.
Drug: Treatment A: Naloxone Nasal Spray
Participants received naloxone nasal spray following a 10 hour fast.

Drug: Treatment B: Naloxone Nasal Spray
Participants received naloxone nasal spray following a 10 hour fast.

Drug: Treatment C: Naloxone HCl Intravenous (IV) Injection
Participants received naloxone HCl IV injection following a 10 hour fast.

Drug: Treatment D: Naloxone HCl Intramuscular (IM) Injection
Participants received naloxone HCl IM injection following a 10 hour fast.

Experimental: Cohort 2: Treatment Sequence B-C-D-A
Participants received Treatment B on Day 1 of Period 1, Treatment C on Day 1 of Period 2, Treatment D on Day 1 of Period 3 and Treatment A on Day 1 of Period 4.
Drug: Treatment A: Naloxone Nasal Spray
Participants received naloxone nasal spray following a 10 hour fast.

Drug: Treatment B: Naloxone Nasal Spray
Participants received naloxone nasal spray following a 10 hour fast.

Drug: Treatment C: Naloxone HCl Intravenous (IV) Injection
Participants received naloxone HCl IV injection following a 10 hour fast.

Drug: Treatment D: Naloxone HCl Intramuscular (IM) Injection
Participants received naloxone HCl IM injection following a 10 hour fast.

Experimental: Cohort 3: Treatment Sequence C-A-B-D
Participants received Treatment C on Day 1 of Period 1, Treatment A on Day 1 of Period 2, Treatment B on Day 1 of Period 3 and Treatment D on Day 1 of Period 4.
Drug: Treatment A: Naloxone Nasal Spray
Participants received naloxone nasal spray following a 10 hour fast.

Drug: Treatment B: Naloxone Nasal Spray
Participants received naloxone nasal spray following a 10 hour fast.

Drug: Treatment C: Naloxone HCl Intravenous (IV) Injection
Participants received naloxone HCl IV injection following a 10 hour fast.

Drug: Treatment D: Naloxone HCl Intramuscular (IM) Injection
Participants received naloxone HCl IM injection following a 10 hour fast.

Experimental: Cohort 4: Treatment Sequence D-B-A-C
Participants received Treatment D on Day 1 of Period 1, Treatment B on Day 1 of Period 2, Treatment A on Day 1 of Period 3 and Treatment C on Day 1 of Period 4.
Drug: Treatment A: Naloxone Nasal Spray
Participants received naloxone nasal spray following a 10 hour fast.

Drug: Treatment B: Naloxone Nasal Spray
Participants received naloxone nasal spray following a 10 hour fast.

Drug: Treatment C: Naloxone HCl Intravenous (IV) Injection
Participants received naloxone HCl IV injection following a 10 hour fast.

Drug: Treatment D: Naloxone HCl Intramuscular (IM) Injection
Participants received naloxone HCl IM injection following a 10 hour fast.




Primary Outcome Measures :
  1. Area Under the Curve From Time 0 to the Last Measured Concentration (AUC0-t) for Unconjugated Naloxone [ Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose ]
  2. AUC Extrapolated to Infinity (AUC0-inf) for Unconjugated Naloxone [ Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose ]
  3. Maximum Plasma Concentration (Cmax) for Unconjugated Naloxone [ Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose ]
  4. Time to Reach Maximum Plasma Concentration (Tmax) for Unconjugated Naloxone [ Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose ]
  5. Time Prior to the First Measurable (Non-Zero) Concentration (Tlag) for Unconjugated Naloxone [ Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose ]
  6. Elimination Rate Constant (λz) for Unconjugated Naloxone [ Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose ]
  7. Elimination Half-Life (t1/2) of Unconjugated Naloxone [ Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose ]
  8. Partial Area Under the Concentration Curve (AUC) of Unconjugated Naloxone [ Time Frame: Pre-dose and at multiple time points up to 24 hours post-dose ]

Secondary Outcome Measures :
  1. Plasma Concentrations of Unconjugated Naloxone [ Time Frame: Pre-dose and at multiple time points up to 2 hours post-dose ]
  2. Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 to Day 14 ]
    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not thought to be related to the investigational product. A serious AE (SAE) is any AE that results in death, is life threatening, requires hospitalization or prolongs existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is medically significant or requires intervention.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • A minimum body weight of 50 kg. Body mass index (BMI) between 18.0 and 32.0 kg/m2
  • A seated blood pressure between 90 and 140 mmHg systolic/50 and 90 mmHg diastolic
  • Female subjects had a negative serum β human chorionic gonadotropin (β-hCG) pregnancy test at screening

Exclusion Criteria:

  • A known allergy or history of significant adverse reaction to naloxone, other opioids or related compounds, or to any of the excipients
  • Any documented clinically significant infection, injury, or illness within 1 month prior to screening
  • An active malignancy of any type, or had been diagnosed with cancer within 5 years prior to screening
  • A documented history of alcohol or drug abuse/dependence/misuse or narcotic analgesic abuse/dependence/misuse within 2 years prior to screening
  • A positive urine test result for alcohol, drugs, or cotinine at screening or check-in
  • A condition that the investigator believed would have interfered with the ability to provide informed consent or comply with study instructions, or that could confound the interpretation of the study results or put the subject at undue risk
  • Used any opioids for 30 days prior to Day 1
  • Required treatment with monoamine oxidase inhibitors (MAOIs) within 30 days prior to Day 1 and during the study.
  • Presence of an ongoing upper respiratory infection, rhinitis, rhinorrhea, or nasal congestions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03827642


Locations
Layout table for location information
United States, Texas
Worldwide Clinical Trials
San Antonio, Texas, United States, 78217
Sponsors and Collaborators
INSYS Therapeutics Inc
Investigators
Layout table for investigator information
Study Director: Giovanni DeCastro INSYS Therapeutics Inc

Layout table for additonal information
Responsible Party: INSYS Therapeutics Inc
ClinicalTrials.gov Identifier: NCT03827642     History of Changes
Other Study ID Numbers: INS012-18-119
First Posted: February 1, 2019    Key Record Dates
Last Update Posted: February 1, 2019
Last Verified: January 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Naloxone
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents